Aster DM Quality Care Ltd (ASTERDM) Q1 FY27 Results Analysis: PAT Falls 25%, Revenue Surges 22%
Aster DM Quality Care Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 1,310.68 Cr (+21.60% YoY) and PAT growth of -68.70% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 1,310.68 Cr (+21.60% YoY) |
| PAT (Q1) | Rs. 29.28 Cr (-68.70% YoY) |
| EBITDA margin | 19.53% (+82 bps YoY) |
| EPS (Q1) | Rs. 0.31 (-81.44% YoY) |
| Market cap | Rs. 73,412.33 Cr |
| CMP | Rs. 842.10 |
Quarter Snapshot
Revenue grew 21.6% YoY with 82bps margin expansion, but reported PAT was hit by a Rs.114 Cr merger charge. Normalized PAT declined 25% YoY, reflecting greenfield ramp-up costs and wage inflation. The merger with QCIL, effective July 1, 2026, positions the company for synergy benefits, but near-term execution remains key.
Key Investment Insights
Key Positives
- Revenue grew 21.60% YoY to Rs.1,310.68 Cr, strongest quarterly growth in recent quarters
- EBITDA margin before exceptional improved 82 bps YoY to 19.53%, demonstrating operating leverage
- Hospitals & Clinics segment margin expanded 211 bps to 18.70%, the highest Q1 level in recent years
- Labs segment result nearly tripled YoY, margin expanding from 2.82% to 7.04%
- Credit rating upgraded to CRISIL AA+/Stable and ICRA AA/Stable post-merger
- Finance costs nearly flat (+1.43% YoY) despite higher debt, reflecting rating upgrade
Risk Factors
- Reported PAT collapsed 68.70% YoY due to exceptional merger charge of Rs.114.38 Cr
- Normalized PAT declined ~25% YoY, indicating underlying profitability pressure from greenfield ramp-up costs and nurse wage impact
- Employee costs grew 24.33% YoY, outpacing revenue growth of 21.60%, partly due to nurse wage settlement
- Standalone EBITDA margin before exceptional contracted 153 bps YoY to 20.25%, suggesting margin pressure at parent level
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.